Drug Profile
PH 45
Latest Information Update: 06 Feb 2023
Price :
$50
*
At a glance
- Originator Pherin Pharmaceuticals
- Class
- Mechanism of Action Testosterone antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Benign prostatic hyperplasia
Most Recent Events
- 02 Feb 2023 Pherin Pharmaceuticals has been acquired by VistaGen Therapeutics
- 04 Nov 2017 No recent reports of development identified for preclinical development in Benign-prostatic-hyperplasia in USA (Intranasal)
- 17 Jan 2011 Preclinical development is ongoing in USA